Galera Therapeutics Inc

NASDAQ:GRTXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Mar 28, 2024

Show headlines and story abstract

• Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates, from 7:00AM ET on Thursday Mar 28, 2024 by GlobeNewswire

  7:00AM ET on Thursday Mar 28, 2024 by GlobeNewswire
  Companies Mentioned: GRTX

• Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates, from 7:00AM ET on Thursday Mar 28, 2024 by Dow Jones

  7:00AM ET on Thursday Mar 28, 2024 by Dow Jones
  Companies Mentioned: GRTX
  
  United States; undesirable side effects from Galera's product candidates; risks relating to the regulatory approval process; failure to capitalize on more profitable product candidates or indications; ability to receive or maintain Breakthrough Therapy, Orphan Drug or Fast Track Designations for product candidates; failure to obtain regulatory approval of product candidates in the United States or other jurisdictions; ongoing regulatory obligations and continued regulatory review; risks related to commercialization; risks related to competition; ability to retain key employees; risks related to intellectual property; inability to maintain collaborations or the failure of these collaborations; Galera's reliance on third parties; the possibility of system failures or security breaches; liability related to the privacy of health information obtained from clinical trials and product liability lawsuits; environmental, health and safety laws and regulations; Galera may not be able to enter into any desired strategic alternative or partnership on a timely basis, on acceptable terms, or at all; if Galera is unable to secure additional funding or enter into any desired strategic alternative or partnership, it may need to cease operations; risks related to ownership of Galera's common stock; the possibility of Galera's common stock being delisted from The Nasdaq Global Market; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption "Risk Factors" in Galera's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (SEC) and Galera's other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any forward-looking statements speak only as of the date of this press release and are based on information available to Galera as of the date of this release, and Galera assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
  

• *DJ Galera Therapeutics 4Q Loss/Shr 10c >GRTX, from 7:00AM ET on Thursday Mar 28, 2024 by Dow Jones

  7:00AM ET on Thursday Mar 28, 2024 by Dow Jones
  Companies Mentioned: GRTX